{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T07:49:22Z","timestamp":1776412162337,"version":"3.51.2"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01MH131480"],"award-info":[{"award-number":["R01MH131480"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["BA2067\/14-1"],"award-info":[{"award-number":["BA2067\/14-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["227167\/A\/23\/Z"],"award-info":[{"award-number":["227167\/A\/23\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"South Africa Population Research Infrastructure Network"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is limited evidence on how the rollout of dolutegravir (DTG) has affected retention in care, tuberculosis (TB) disease risk, and viral load suppression (VLS) among people living with HIV (PLHIV) in routine program settings. This study evaluated associations between DTG rollout and VLS, risk of developing TB disease, and retention in care in rural KwaZulu-Natal (KZN), South Africa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We employed a retrospective cohort study of PLHIV aged 15 and above, followed up from 1 October 2019 to 31 December 2023 in a rural sub-district of KZN. We grouped antiretroviral therapy (ART) regimens into DTG-containing and non-DTG-containing regimens. We classified PLHIV as virally suppressed or non-suppressed based on a VLS threshold of &amp;lt;400\u2005copies\/mL. We used Kaplan-Meier survival curves to describe the transition to DTG over time. We applied Cox proportional-hazards models to evaluate associations between DTG rollout and VLS, the risk of developing TB, and retention in care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 69 919 PLHIV included in the DTG rollout cohort, approximately 70% (n = 48 598) transitioned to DTG-containing regimens during the 4-year follow-up period. Compared with non-DTG regimens, DTG use was associated with a greater likelihood of VLS (aHR 1.24, 95% CI 1.10\u20131.29), retention in care (aHR 1.20, 95% CI 1.11\u20131.30), and lower risk of TB disease (aHR 0.68, 95% CI .54\u2013.87).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings support the sustained rollout of DTG-based regimens and emphasize the importance of continuous monitoring to assess their long-term associations and programmatic performance in comparable settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag156","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T05:52:17Z","timestamp":1773899537000},"source":"Crossref","is-referenced-by-count":0,"title":["Effect of the Scale-Up of Dolutegravir on Retention in Care, Risk of Developing Tuberculosis and Viral Load Suppression Among People Living With HIV: Analysis of Routine HIV Clinical Data in Rural KwaZulu-Natal, South Africa (2019\u201323)"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4308-0103","authenticated-orcid":false,"given":"Reuben Christopher","family":"Moyo","sequence":"first","affiliation":[{"name":"South African Centre for Epidemiological Modelling and Analysis (SACEMA), Centre for Epidemic Response and Innovation (CERI), School for Data Science and Computational Thinking, Stellenbosch University , Stellenbosch ,","place":["South Africa"]},{"name":"Department of Global Health, Division of Epidemiology and Biostatistics, Faculty of Medicine and Health Sciences, Stellenbosch University , Cape Town ,","place":["South Africa"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elphas","family":"Okango","sequence":"additional","affiliation":[{"name":"Africa Health Research Institute , Durban ,","place":["South Africa"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7879-2173","authenticated-orcid":false,"given":"Larisse","family":"Bolton","sequence":"additional","affiliation":[{"name":"South African Centre for Epidemiological Modelling and Analysis (SACEMA), Centre for Epidemic Response and Innovation (CERI), School for Data Science and Computational Thinking, Stellenbosch University , Stellenbosch ,","place":["South Africa"]},{"name":"Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town ,","place":["South Africa"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margot","family":"Otto","sequence":"additional","affiliation":[{"name":"South African Centre for Epidemiological Modelling and Analysis (SACEMA), Centre for Epidemic Response and Innovation (CERI), School for Data Science and Computational Thinking, Stellenbosch University , Stellenbosch ,","place":["South Africa"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0787-6702","authenticated-orcid":false,"given":"Ntombifuthi","family":"Blose","sequence":"additional","affiliation":[{"name":"South African Centre for Epidemiological Modelling and Analysis (SACEMA), Centre for Epidemic Response and Innovation (CERI), School for Data Science and Computational Thinking, Stellenbosch University , Stellenbosch ,","place":["South Africa"]},{"name":"Department of Global Health, Division of Epidemiology and Biostatistics, Faculty of Medicine and Health Sciences, Stellenbosch University , Cape Town ,","place":["South Africa"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6261-8717","authenticated-orcid":false,"given":"Tumelo","family":"Sereo","sequence":"additional","affiliation":[{"name":"South African Centre for Epidemiological Modelling and Analysis (SACEMA), Centre for Epidemic Response and Innovation (CERI), School for Data Science and Computational Thinking, Stellenbosch University , Stellenbosch ,","place":["South Africa"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1086-6011","authenticated-orcid":false,"given":"Letoao","family":"Shoeshoe","sequence":"additional","affiliation":[{"name":"South African Centre for Epidemiological Modelling and Analysis (SACEMA), Centre for Epidemic Response and Innovation (CERI), School for Data Science and Computational Thinking, Stellenbosch University , Stellenbosch ,","place":["South Africa"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilfred","family":"Otambo","sequence":"additional","affiliation":[{"name":"South African Centre for Epidemiological Modelling and Analysis (SACEMA), Centre for Epidemic Response and Innovation (CERI), School for Data Science and Computational Thinking, Stellenbosch University , Stellenbosch ,","place":["South Africa"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dickman","family":"Gareta","sequence":"additional","affiliation":[{"name":"Africa Health Research Institute , Durban ,","place":["South Africa"]},{"name":"Institute of Social and Preventive Medicine, University of Bern , Bern ,","place":["Switzerland"]},{"name":"Graduate School for Health Sciences, University of Bern , Bern ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter S","family":"Nyasulu","sequence":"additional","affiliation":[{"name":"Department of Global Health, Division of Epidemiology and Biostatistics, Faculty of Medicine and Health Sciences, Stellenbosch University , Cape Town ,","place":["South Africa"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0912-0984","authenticated-orcid":false,"given":"Paul","family":"Mee","sequence":"additional","affiliation":[{"name":"Lincoln Institute for Rural and Coastal Health, College of Health and Science, University of Lincoln , Lincoln ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0926-710X","authenticated-orcid":false,"given":"Richard J","family":"Lessells","sequence":"additional","affiliation":[{"name":"KwaZulu-Natal Research and Innovation Sequencing Platform (KRISP), University of KwaZulu-Natal , Durban, KwaZulu-Natal ,","place":["South Africa"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9797-0000","authenticated-orcid":false,"given":"Frank Courteney","family":"Tanser","sequence":"additional","affiliation":[{"name":"South African Centre for Epidemiological Modelling and Analysis (SACEMA), Centre for Epidemic Response and Innovation (CERI), School for Data Science and Computational Thinking, Stellenbosch University , Stellenbosch ,","place":["South Africa"]},{"name":"Department of Global Health, Division of Epidemiology and Biostatistics, Faculty of Medicine and Health Sciences, Stellenbosch University , Cape Town ,","place":["South Africa"]},{"name":"Africa Health Research Institute , Durban ,","place":["South Africa"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"2026041703021142800_ofag156-B1","author":"Human Sciences Research Council (HSRC)"},{"key":"2026041703021142800_ofag156-B2","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.7196\/SAMJ.2021.v111i12.14584","article-title":"A natural history of efavirenz drug-induced liver injury","volume":"111","author":"Maughan","year":"2021","journal-title":"S Afr Med J"},{"key":"2026041703021142800_ofag156-B3","doi-asserted-by":"crossref","first-page":"e1003397","DOI":"10.1371\/journal.pmed.1003397","article-title":"Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: a modeling study","volume":"17","author":"Hauser","year":"2020","journal-title":"PLoS Med"},{"key":"2026041703021142800_ofag156-B4","doi-asserted-by":"crossref","first-page":"787","DOI":"10.7196\/SAMJ.2022.v112i10.16596","article-title":"Dolutegravir as first-line antiretroviral therapy in South Africa: beware the one-size-fits-all approach","volume":"112","author":"Bangalee","year":"2022","journal-title":"S Afr Med J"},{"key":"2026041703021142800_ofag156-B5","author":"aidsmap"},{"key":"2026041703021142800_ofag156-B6","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/S2352-3018(18)30317-5","article-title":"Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study","volume":"6","author":"Phillips","year":"2019","journal-title":"Lancet HIV"},{"key":"2026041703021142800_ofag156-B7","author":"Milanga"},{"key":"2026041703021142800_ofag156-B8","doi-asserted-by":"crossref","first-page":"614","DOI":"10.7326\/M18-3358","article-title":"Risks and benefits of dolutegravir- and efavirenz-based strategies for South African women with HIV of child-bearing potential: a modeling study","volume":"170","author":"Dugdale","year":"2019","journal-title":"Ann Intern Med"},{"key":"2026041703021142800_ofag156-B9","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1186\/s12879-021-06851-9","article-title":"Patient experiences of switching from efavirenz- to dolutegravir-based antiretroviral therapy: a qualitative study in Uganda","volume":"21","author":"Twimukye","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2026041703021142800_ofag156-B10","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.eimc.2020.02.018","article-title":"Neuropsychiatric adverse effects of dolutegravir in real-life clinical practice","volume":"39","author":"Povar-Echeverr\u00eda","year":"2021","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"key":"2026041703021142800_ofag156-B11","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1016\/S2352-3018(23)00047-4","article-title":"Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study","volume":"10","author":"Dorward","year":"2023","journal-title":"Lancet HIV"},{"key":"2026041703021142800_ofag156-B12","author":"Asare"},{"key":"2026041703021142800_ofag156-B13","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/cid\/civ981","article-title":"The cost-effectiveness and budget impact of 2-drug dolutegravir-lamivudine regimens for the treatment of HIV infection in the United States","volume":"62","author":"Girouard","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026041703021142800_ofag156-B14","author":"Human Sciences Research Council"},{"key":"2026041703021142800_ofag156-B15","author":"Osler"},{"key":"2026041703021142800_ofag156-B16","doi-asserted-by":"crossref","first-page":"174","DOI":"10.7196\/SAMJ.2019.v109i3.13456","article-title":"How accurately do routinely reported HIV viral load suppression proportions reflect progress towards the 90-90-90 target in the population on antiretroviral treatment in Khayelitsha, South Africa?","volume":"109","author":"Euvrard","year":"2019","journal-title":"S Afr Med J"},{"key":"2026041703021142800_ofag156-B17","doi-asserted-by":"crossref","first-page":"e0001728","DOI":"10.1371\/journal.pgph.0001728","article-title":"Small area analysis of HIV viral load suppression patterns in a high priority district (2012\u20132016), South Africa","volume":"3","author":"Chimoyi","year":"2023","journal-title":"PLOS Glob Public Health"},{"key":"2026041703021142800_ofag156-B18","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3851\/IMP3371","article-title":"Recording of HIV viral loads and viral suppression in South African patients receiving antiretroviral treatment: a multicentre cohort study","volume":"25","author":"Pillay","year":"2020","journal-title":"Antivir Ther"},{"key":"2026041703021142800_ofag156-B19","author":"World Health Organisation"},{"key":"2026041703021142800_ofag156-B20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3389\/fpubh.2020.00100","article-title":"Misreporting of patient outcomes in the South African National HIV Treatment Database: consequences for programme planning, monitoring, and evaluation","volume":"8","author":"Etoori","year":"2020","journal-title":"Front Public Health"},{"key":"2026041703021142800_ofag156-B21","author":"StataCorp","year":"2023"},{"key":"2026041703021142800_ofag156-B22","article-title":"Diagnostics for the cox model","volume":"24","author":"Xue","year":"2017","journal-title":"Commun Stat Appl Methods"},{"key":"2026041703021142800_ofag156-B23","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijantimicag.2019.04.009","article-title":"Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin","volume":"54","author":"Wang","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2026041703021142800_ofag156-B24","doi-asserted-by":"crossref","DOI":"10.1099\/jmm.0.001566","article-title":"JMM profile: rifampicin: a broad-spectrum antibiotic","volume":"71","author":"Hardie","year":"2022","journal-title":"J Med Microbiol"},{"key":"2026041703021142800_ofag156-B25","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.4102\/sajhivmed.v24i1.1528","article-title":"Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults: 2023 update","volume":"24","author":"Nel","year":"2023","journal-title":"South Afr J HIV Med"},{"key":"2026041703021142800_ofag156-B26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12981-025-00810-z","article-title":"Dolutegravir rollout for treatment of HIV with a focus on advanced disease and tuberculosis coinfection: findings from rural KwaZulu-Natal, South Africa (2019\u20132023)","volume":"22","author":"Moyo","year":"2025","journal-title":"AIDS Res Ther"},{"key":"2026041703021142800_ofag156-B27","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0140-6736(23)00877-2","article-title":"The risk of sexual transmission of HIV in individuals with low-level HIV viraemia: a systematic review","volume":"402","author":"Broyles","year":"2023","journal-title":"Lancet"},{"key":"2026041703021142800_ofag156-B28","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1177\/0956462419846726","article-title":"Viral suppression and HIV transmission behaviors among hospitalized patients living with HIV","volume":"30","author":"Pan","year":"2019","journal-title":"Int J STD AIDS"},{"key":"2026041703021142800_ofag156-B29","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus Abacavir\u2013lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"key":"2026041703021142800_ofag156-B30","doi-asserted-by":"crossref","first-page":"20022","DOI":"10.7448\/IAS.18.1.20022","article-title":"Tracing defaulters in HIV prevention of mother-to-child transmission programmes through community health workers: results from a rural setting in Zimbabwe","volume":"18","author":"Vogt","year":"2015","journal-title":"J Int AIDS Soc"},{"key":"2026041703021142800_ofag156-B31","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/QAI.0000000000003657","article-title":"Brief report: resistance to dolutegravir in treatment-experienced patients in South Africa: a retrospective cohort study","volume":"99","author":"Zhao","year":"2025","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026041703021142800_ofag156-B32","doi-asserted-by":"crossref","first-page":"e698","DOI":"10.1016\/S2214-109X(24)00553-9","article-title":"Predicted dolutegravir resistance in people living with HIV in South Africa during 2020\u201335: a modelling study","volume":"13","author":"Loosli","year":"2025","journal-title":"Lancet Glob Health"},{"key":"2026041703021142800_ofag156-B33","author":"South African National Department of Health (SA-NDoH)"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag156\/67396556\/ofag156.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/4\/ofag156\/68099324\/ofag156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/4\/ofag156\/68099324\/ofag156.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T07:02:31Z","timestamp":1776409351000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag156\/8528239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag156","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,3,19]]},"article-number":"ofag156"}}